Predicting stereotactic radiosurgery outcomes with multi-observer qualitative appearance labelling versus MRI radiomics.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 10 05 2023
accepted: 17 11 2023
medline: 30 11 2023
pubmed: 29 11 2023
entrez: 28 11 2023
Statut: epublish

Résumé

Qualitative observer-based and quantitative radiomics-based analyses of T1w contrast-enhanced magnetic resonance imaging (T1w-CE MRI) have both been shown to predict the outcomes of brain metastasis (BM) stereotactic radiosurgery (SRS). Comparison of these methods and interpretation of radiomics-based machine learning (ML) models remains limited. To address this need, we collected a dataset of n = 123 BMs from 99 patients including 12 clinical features, 107 pre-treatment T1w-CE MRI radiomic features, and BM post-SRS progression scores. A previously published outcome model using SRS dose prescription and five-way BM qualitative appearance scoring was evaluated. We found high qualitative scoring interobserver variability across five observers that negatively impacted the model's risk stratification. Radiomics-based ML models trained to replicate the qualitative scoring did so with high accuracy (bootstrap-corrected AUC = 0.84-0.94), but risk stratification using these replicated qualitative scores remained poor. Radiomics-based ML models trained to directly predict post-SRS progression offered enhanced risk stratification (Kaplan-Meier rank-sum p = 0.0003) compared to using qualitative appearance. The qualitative appearance scoring enabled interpretation of the progression radiomics-based ML model, with necrotic BMs and a subset of heterogeneous BMs predicted as being at high-risk of post-SRS progression, in agreement with current radiobiological understanding. Our study's results show that while radiomics-based SRS outcome models out-perform qualitative appearance analysis, qualitative appearance still provides critical insight into ML model operation.

Identifiants

pubmed: 38017055
doi: 10.1038/s41598-023-47702-8
pii: 10.1038/s41598-023-47702-8
pmc: PMC10684869
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20977

Informations de copyright

© 2023. The Author(s).

Références

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):996-1001
pubmed: 19783374
J Clin Oncol. 2020 Nov 10;38(32):3773-3784
pubmed: 32931399
Oncologist. 2013;18(3):330-5
pubmed: 23429647
Med Phys. 2021 Sep;48(9):5522-5530
pubmed: 34287940
Radiother Oncol. 2022 Jan;166:37-43
pubmed: 34801629
Sci Rep. 2022 Dec 5;12(1):20975
pubmed: 36471160
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Sci Rep. 2019 Dec 27;9(1):19830
pubmed: 31882597
Neuro Oncol. 2020 Jun 9;22(6):797-805
pubmed: 31956919
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):25-30
pubmed: 9300736
Cancers (Basel). 2021 Aug 10;13(16):
pubmed: 34439186
Radiology. 1999 Jun;211(3):807-14
pubmed: 10352610
Med Phys. 2022 Nov;49(11):7167-7178
pubmed: 35727568
Radiat Med. 1999 Jul-Aug;17(4):311-5
pubmed: 10510905
J Neurosurg. 2015 Aug;123(2):373-86
pubmed: 25978710
Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):375-83
pubmed: 9069310
Neurosurgery. 2018 Sep 1;83(3):345-353
pubmed: 29126142
J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Radiother Oncol. 2023 Jan;178:109424
pubmed: 36435336
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Front Oncol. 2021 Jan 11;10:569461
pubmed: 33505904
Sci Rep. 2021 Nov 3;11(1):21620
pubmed: 34732781
Magn Reson Imaging. 2004 Jan;22(1):81-91
pubmed: 14972397
Front Oncol. 2023 Mar 13;13:1114194
pubmed: 36994193
Ann Oncol. 2021 Nov;32(11):1332-1347
pubmed: 34364998
Eur Radiol. 2022 Apr;32(4):2266-2276
pubmed: 34978579
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Cancer. 1997 Dec 1;80(11):2075-83
pubmed: 9392329
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):139-46
pubmed: 11316557
Clin Transl Radiat Oncol. 2021 May 08;29:27-32
pubmed: 34095557
IEEE J Transl Eng Health Med. 2022 Nov 04;11:13-22
pubmed: 36478770
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
pubmed: 23149893

Auteurs

David A DeVries (DA)

Department of Medical Biophysics, Western University, London, N6A 3K7, Canada. ddevrie8@uwo.ca.
Gerald C. Baines Centre, London Health Sciences Centre, London, N6A 5W9, Canada. ddevrie8@uwo.ca.

Terence Tang (T)

Department of Radiation Oncology, London Health Sciences Centre, London, N6A 5W9, Canada.

Ali Albweady (A)

Department of Radiology, Unaizah College of Medicine and Medical Sciences, Qassim University, 56219, Buraidah, Saudi Arabia.

Andrew Leung (A)

Department of Medical Imaging, Western University, London, N6A 3K7, Canada.

Joanna Laba (J)

Department of Radiation Oncology, London Health Sciences Centre, London, N6A 5W9, Canada.
Department of Oncology, Western University, London, N6A 3K7, Canada.

Carol Johnson (C)

Gerald C. Baines Centre, London Health Sciences Centre, London, N6A 5W9, Canada.

Frank Lagerwaard (F)

Department of Radiation Oncology, Amsterdam University Medical Centre, Amsterdam, 1081, The Netherlands.

Jaap Zindler (J)

Department of Radiation Oncology, Haaglanden Medical Centre, Den Hague, 2512VA, The Netherlands.
Holland Proton Centre, Delft, 2629JA, The Netherlands.

George Hajdok (G)

Department of Medical Biophysics, Western University, London, N6A 3K7, Canada.

Aaron D Ward (AD)

Department of Medical Biophysics, Western University, London, N6A 3K7, Canada.
Gerald C. Baines Centre, London Health Sciences Centre, London, N6A 5W9, Canada.
Department of Oncology, Western University, London, N6A 3K7, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH